Founder and CEO
Lars has a proven track record in drug discovery and business development within the pharmaceutical industry with over 25 years wide-ranging research and business experience in senior positions at Karo Bio AB following several years at Pharmacia.
Mathias Färnegårdh, Ph.D
Founder and CSO
Has two decades of experience of leadership in drug discovery, initiating and driving innovative projects with international partners. He has an in depth understanding of target biology and a particular interest in immunology.
Konrad Koehler, Ph.D.
Founder and Principal Scientist Medicinal Chemistry
Over 25 years’ experience in drug discovery at Searle R&D, Merck Italia, Solvay Pharmaceuticals GmbH, Karo Bio AB, and Beactica AB instrumental in establishing drug discovery collaborations with which resulted in four drug candidates that underwent clinical trials.
Maria holds a M. Sc. in Engineering Biology from Linköpings Tekniska Högskola. She has extensive experience in in vitro pharmacology and has been working over a decade with assay development in projects from early drug discovery phase to GMP assays for use in clinical stage projects. Maria has previously worked at Karo Bio AB and Cobra Biologics AB.
Eva Backström Rydin, Ph.D
Director of Immunology
Eva has a PhD from Karolinska Institutet with focus on neuroimmunology. She has since moved into the field of immunology and has over 14 years experience from research, early drug discovery to advanced immunotherapy in clinical stage at the Terry Fox Laboratory, British Columbia Cancer Agency, SentoClone AB, Karo Bio AB and Pelago Bioscience.